Cargando…

Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival

Overexpression of p53 is the most frequent genetic alteration in breast cancer. Recently, many studies have shown that the expression of mutant p53 differs for each subtype of breast cancer and is associated with different prognoses. In this study, we aimed to determine the suitable cut-off value to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Se Kyung, Bae, Soo Youn, Lee, Jun Ho, Lee, Hyun-Chul, Yi, Hawoo, Kil, Won Ho, Lee, Jeong Eon, Kim, Seok Won, Nam, Seok Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524613/ https://www.ncbi.nlm.nih.gov/pubmed/26241661 http://dx.doi.org/10.1371/journal.pone.0124658

Ejemplares similares

Molecular subtyping of ependymoma and prognostic impact of Ki-67
por: Lim, Ka Young, et al.
Publicado: (2021)

Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes
por: Viale, Giuseppe, et al.
Publicado: (2019)

MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers
por: Sadeghian, Dorsay, et al.
Publicado: (2022)

Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment
por: Kwon, Ah-Young, et al.
Publicado: (2019)

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer
por: Bae, Soo Youn, et al.
Publicado: (2015)

Expression of Cyclooxygenase-2, p53 and Ki-67 in Gastric Cancer
por: Joo, Young-Eun, et al.
Publicado: (2006)

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
por: Ciruelos, E, et al.
Publicado: (2011)

Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?
por: Oddó, David, et al.
Publicado: (2018)

Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
por: Inic, Zorka, et al.
Publicado: (2014)

Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival Outcome Compared with Ductal Carcinoma In Situ
por: Min, Yejin, et al.
Publicado: (2013)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
por: Keam, Bhumsuk, et al.
Publicado: (2011)

Prognostic impact of Ki-67 in patients with gastric cancer—the importance of depth of invasion and histologic differentiation
por: Ko, Gyung Hyuck, et al.
Publicado: (2017)

Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2023)

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
por: Jacquemier, Jocelyne, et al.
Publicado: (2009)

Comparison of the Characteristics of Medullary Breast Carcinoma and Invasive Ductal Carcinoma
por: Park, Inhye, et al.
Publicado: (2013)

Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer
por: YUAN, PENG, et al.
Publicado: (2016)

A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method
por: Jang, Min Hye, et al.
Publicado: (2017)

Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer
por: Kim, Hohyun, et al.
Publicado: (2015)

Significance of p53 and ki-67 expression in prostate cancer
por: Verma, Renuka, et al.
Publicado: (2015)

Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy
por: Kil, Won Ho, et al.
Publicado: (2014)

Retraction note to: "Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy"
por: Kil, Won Ho, et al.
Publicado: (2015)

Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
por: Park, Jin Young, et al.
Publicado: (2013)

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
por: Cheang, Maggie C. U., et al.
Publicado: (2009)

The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer
por: Go, Se-Il, et al.
Publicado: (2019)

Prognostic Value of Immunohistochemical Staining of p53, bcl-2, and Ki-67 in Small Cell Lung Cancer
por: Paik, Kwang Hyun, et al.
Publicado: (2006)

Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
por: Tendl-Schulz, Kristina A., et al.
Publicado: (2020)

Clinical Significance of Ki-67 Labeling Index in Pituitary Macroadenoma
por: Paek, Kyung-Il, et al.
Publicado: (2005)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
por: Noske, Aurelia, et al.
Publicado: (2019)

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
por: Hao, Junmei, et al.
Publicado: (2021)

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022)

Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone.
por: Park, H. R., et al.
Publicado: (1995)

Radiomic prediction models for the level of Ki-67 and p53 in glioma
por: Sun, Xiaojun, et al.
Publicado: (2020)

Immunoexpression of Ki67, p53 and cyclin D1 in osteosarcomas
por: Niculescu, Ştefan Adrian, et al.
Publicado: (2021)

Evaluation of P57, P53 and Ki67 Expression in Meningiomas
por: Küçükosmanoğlu, İlknur, et al.
Publicado: (2022)

Sentinel Lymph Node Biopsy Alone after Neoadjuvant Chemotherapy in Patients with Initial Cytology-Proven Axillary Node Metastasis
por: Kim, Ji Young, et al.
Publicado: (2015)

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
por: Choi, Soon Bo, et al.
Publicado: (2022)

Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score
por: Paik, Soonmyung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vfmumo6n1arm83rv8qtjiaphjk